Kyntra Bio (KYNB) Cash from Financing Activities (2014 - 2026)
Kyntra Bio (KYNB) posted Cash from Financing Activities of -$7000.0 for Q1 2026, up 50.0% sequentially from -$14000.0 in Q4 2025, and up 92.05% YoY from -$3645.0 in Q1 2025.
Kyntra Bio (KYNB) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Cash from Financing Activities for 13 years, with the latest figure at -$7000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 92.05% year-over-year to -$7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$85.9 million (down 48184.83% YoY) and the FY2025 annual result came in at -$86.0 million, down 33636.47% from the prior year.
- Cash from Financing Activities grew to -$7000.0 in Q1 2026 per KYNB's latest filing, from -$14000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $91.5 million in Q2 2023 and troughed at -$85.9 million in Q3 2025.
- A 5-year average of $4.9 million and a median of -$14000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities soared 157112.9% in 2022, then sank 67551.18% in 2025.
- Over 5 years, Cash from Financing Activities stood at $48.7 million in 2022, then tumbled by 100.51% to -$246000.0 in 2023, then surged by 102.03% to $5000.0 in 2024, then plunged by 380.0% to -$14000.0 in 2025, then jumped by 50.0% to -$7000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$7000.0, -$14000.0, and -$85.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | -5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,000.00 |
| Jun 30, 2026 | -5,000.00 |
| Mar 31, 2026 | -7,000.00 |
| Mar 31, 2026 | -7,000.00 |
| Dec 31, 2025 | -14,000.00 |
| Dec 31, 2025 | -14,000.00 |
| Sep 30, 2025 | -85.92 Mn |
| Sep 30, 2025 | -85.92 Mn |
| Jun 30, 2025 | -9,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Mar 31, 2025 | -88,000.00 |
| Mar 31, 2025 | -88,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | -127,000.00 |
| Sep 30, 2024 | -127,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | -165,000.00 |
| Mar 31, 2024 | -165,000.00 |